A Phase 2 interventional study of Background IL-17A Inhibitor Therapy and Recaticimab in Plaque Psoriasis and Dyslipidemia, sponsored by Xiangya Hospital of Central South University. Not yet recruiting at 7 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Xiangya Hospital of Central South University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Dyslipidemias with a site in China — 23 open to participants now, 33 under way, 10 of them phase 3. Dyslipidemias · China.
Among the 75 studies in Dyslipidemias with a site in China, this one is the 40th largest by planned enrollment of the 58 interventional ones that give a count, is one of 9 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 25 of the 32 other live ones, and was the 75th registered.
1,251 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →23 of the 75 studies in Dyslipidemias with a site in China are open now. Recruiting first, the newest first:
Shanghai Minwei Biotechnology Co., Ltd · Sites in China
Ages 18–75
China Medical University, China · Sites in China
Ages 50–75
Peking University Third Hospital · Sites in China
Ages 18–80 · Healthy volunteers
Eddingpharm (Zhuhai) Co., Ltd. · Sites in China
Ages 18+
First Affiliated Hospital of Fujian Medical University · Sites in China
Ages 18+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 17 · Phase 4 12
First in 2008; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 100 across 987 interventional studies indexed under Dyslipidemias.
Median enrollment 210 across the 58 interventional studies, 1,000 across the 17 observational. Of the 33 that completed or were terminated, 8 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 75 have an industry lead sponsor. The 10 most frequent:
Xiangya Hospital of Central South University is the lead sponsor of 177 studies on the registry; 80 are open to participants now.
Xiangya Hospital of Central South University has 1 study filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
8 of the studies in Dyslipidemias with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06834932Phase 3AstraZenecaA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia | 2027-02-22 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT05399992Novartis PharmaceuticalsStudy Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD | 2026-11-23 |
| NCT05749874China National Center for Cardiovascular DiseasesEffects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus | 2026-12-31 |
| NCT07350486First Hospital of China Medical UniversityLLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia | 2027-03-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 75 studies in Dyslipidemias with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter, randomized, double-blind, placebo-controlled trial evaluates recaticimab added to ongoing IL-17A inhibitor therapy in adults with plaque psoriasis, dyslipidemia, and secondary loss of response to their IL-17A inhibitor.
Participants receive recaticimab 150 mg or matching placebo every 4 weeks in addition to their existing IL-17A inhibitor. The primary endpoint is PASI75 response at Week 16.
Both groups receive recaticimab after the Week 16 assessments through Week 32, with safety follow-up at Week 36.
After screening of up to 4 weeks, participants are randomized 1:1 to recaticimab or matching placebo while continuing their established IL-17A inhibitor regimen.
Recaticimab 150 mg or matching placebo is administered subcutaneously at Weeks 0, 4, 8, and 12. After the Week 16 efficacy assessments, both groups receive recaticimab 150 mg at Weeks 16, 20, 24, 28, and 32. Safety follow-up is at Week 36, without study-drug administration. Post-Week 16 comparisons are exploratory.
A prespecified interim analysis may increase total enrollment from 100 to a maximum of 150 participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet all of the following criteria:
Meet the following prior-treatment and prior-response requirements for secondary treatment failure:
Moderate-to-severe plaque psoriasis before starting the current IL-17A inhibitor must be supported by contemporaneous medical records. The investigator must verify the severity classification and its basis with reference to the Chinese Guidelines for the Diagnosis and Treatment of Psoriasis (2023 edition).
The total duration of treatment with the current IL-17A inhibitor before enrollment must be at least 16 weeks. The actual cumulative dose received must be at least 80% of the cumulative dose calculated according to the product-label-recommended regimen over the same treatment period.
A prior good clinical response during treatment with this drug must be supported by verifiable medical records and meet at least one of the following four conditions:
The requirement for documented moderate-to-severe disease before treatment applies to all four pathways. Available pretreatment PASI, BSA, sPGA/IGA, Dermatology Life Quality Index (DLQI), and clinical severity assessments must be recorded; all four scales are not required. The PASI90 pathway requires PASI values from both before and during treatment with that drug. Each other pathway requires the relevant on-treatment record and evidence of moderate-to-severe disease before treatment. The investigator must verify the drug, dates, overall skin involvement, and source of evidence. Patient recall alone or a history of biologic use alone is insufficient. Missing historical scores must not be reconstructed.
Exclusion Criteria:
Participants meeting any of the following criteria are excluded:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency. Recaticimab 150 mg is administered subcutaneously at Weeks 0, 4, 8, and 12. After completion of the Week 16 PASI75 primary endpoint assessment and other prespecified efficacy assessments, participants receive recaticimab 150 mg subcutaneously at Weeks 16, 20, 24, 28, and 32. A safety follow-up visit is conducted at Week 36; no recaticimab or placebo is administered at that visit.
Drug: Background IL-17A Inhibitor Therapy · Drug: Recaticimab
Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency. Matching placebo is administered subcutaneously at Weeks 0, 4, 8, and 12. After completion of the Week 16 PASI75 primary endpoint assessment and other prespecified efficacy assessments, participants switch to recaticimab 150 mg administered subcutaneously at Weeks 16, 20, 24, 28, and 32. A safety follow-up visit is conducted at Week 36; no recaticimab or placebo is administered at that visit.
Drug: Background IL-17A Inhibitor Therapy · Drug: Recaticimab · Drug: Matching Placebo
Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency.
Recaticimab 150 mg is administered subcutaneously every 4 weeks. Participants assigned to the experimental arm receive recaticimab at Weeks 0, 4, 8, 12, 16, 20, 24, 28, and 32. Participants assigned to the placebo comparator arm receive recaticimab at Weeks 16, 20, 24, 28, and 32, after completion of the Week 16 primary endpoint and other prespecified efficacy assessments.
Matching placebo is administered subcutaneously to participants assigned to the placebo comparator arm at Weeks 0, 4, 8, and 12 during the double-blind, placebo-controlled period.
Percentage of participants achieving PASI75 at Week 16
PASI75 is defined as a ≥75% reduction in the Psoriasis Area and Severity Index (PASI) score from the Week 0 randomization baseline.
Time frame: Week 16
Mean percentage improvement from baseline in sPGA × BSA at Week 16
sPGA × BSA is the sPGA score multiplied by affected BSA (%). Mean individual percentage improvement is calculated as 100 × (Week 0 value - Week 16 value) / Week 0 value.
Time frame: Baseline (Week 0) and Week 16
Mean change from baseline in PASI score
Mean change from the Week 0 PASI score. PASI ranges from 0 to 72; higher scores indicate more severe disease.
Time frame: Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Mean percentage improvement from baseline in PASI score
Mean of individual percentage improvements in PASI: 100 × (Week 0 score - post-baseline score) / Week 0 score. Higher values indicate greater improvement.
Time frame: Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Percentage of participants achieving PASI50
Percentage with at least a 50% reduction in PASI from the Week 0 randomization baseline.
Time frame: Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Percentage of participants achieving PASI90
Percentage with at least a 90% reduction in PASI from the Week 0 randomization baseline.
Time frame: Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Percentage of participants achieving PASI100
Percentage with a 100% reduction in PASI from the Week 0 randomization baseline.
Time frame: Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Percentage of participants with sPGA 0 or 1
Percentage with a static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear). The scale ranges from 0 to 4.
Time frame: Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Change from baseline in skin itch Numeric Rating Scale score
Change from Week 0 in skin itch Numeric Rating Scale (NRS) score, ranging from 0 (no itch) to 10 (worst imaginable itch).
Time frame: Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Change from baseline in Dermatology Life Quality Index score
Change from the last valid pre-dose Dermatology Life Quality Index (DLQI) score. Scores range from 0 to 30; higher scores indicate worse quality of life.
Time frame: Baseline and Weeks 8 and 16; exploratory extension/follow-up at Weeks 32 and 36
Percentage change from baseline in low-density lipoprotein cholesterol
Percentage change in LDL-C: 100 × (post-baseline - baseline) / baseline. Baseline is the last valid pre-dose measurement.
Time frame: Baseline and Weeks 8 and 16; exploratory extension at Weeks 24 and 32
Participants with treatment-emergent adverse events
Number and percentage of participants with adverse events occurring after the first study dose through the final safety follow-up visit.
Time frame: From the first study dose through Week 36
Plan to share: No
Start is estimated for Nov 2026; primary completion for Apr 2028, 17 months later.
Of 43 phase 2 interventional studies under Dyslipidemias, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 21. This study's planned 17 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Recaticimab
Xiangya Hospital of Central South University →